2/25
07:15 am
vtrs
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Yahoo! Finance]
Low
Report
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Yahoo! Finance]
2/25
06:59 am
vtrs
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Low
Report
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
2/25
12:52 am
vtrs
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow [Yahoo! Finance]
Low
Report
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow [Yahoo! Finance]
2/23
07:54 am
vtrs
Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
Low
Report
Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
2/23
07:48 am
vtrs
Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
Low
Report
Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
2/19
01:08 pm
vtrs
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade [Yahoo! Finance]
Low
Report
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade [Yahoo! Finance]
2/9
03:54 pm
vtrs
Why Viatris (VTRS) Stock Is Up Today [Yahoo! Finance]
Neutral
Report
Why Viatris (VTRS) Stock Is Up Today [Yahoo! Finance]
2/7
02:16 am
vtrs
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment [Yahoo! Finance]
Medium
Report
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment [Yahoo! Finance]
2/3
04:34 pm
vtrs
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Medium
Report
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
2/3
11:00 am
vtrs
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026 [Yahoo! Finance]
Low
Report
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026 [Yahoo! Finance]
2/3
08:55 am
vtrs
Viatris Appoints Matthew J. Maletta as Chief Legal Officer [Yahoo! Finance]
Neutral
Report
Viatris Appoints Matthew J. Maletta as Chief Legal Officer [Yahoo! Finance]
2/3
08:30 am
vtrs
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Low
Report
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
2/2
11:54 am
vtrs
What Are Wall Street Analysts' Target Price for Viatris Stock? [Yahoo! Finance]
Low
Report
What Are Wall Street Analysts' Target Price for Viatris Stock? [Yahoo! Finance]
1/29
01:41 pm
vtrs
Davis Opportunity Fund Annual Review 2026 [Seeking Alpha]
Low
Report
Davis Opportunity Fund Annual Review 2026 [Seeking Alpha]
1/24
07:11 pm
vtrs
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch [Yahoo! Finance]
Low
Report
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch [Yahoo! Finance]
1/24
01:53 am
vtrs
Is Viatris (VTRS) Pricing Reflect Its Recent Multi-Year Share Price Recovery [Yahoo! Finance]
Low
Report
Is Viatris (VTRS) Pricing Reflect Its Recent Multi-Year Share Price Recovery [Yahoo! Finance]
1/23
08:06 am
vtrs
Viatris Earnings Preview: What to Expect [Yahoo! Finance]
Low
Report
Viatris Earnings Preview: What to Expect [Yahoo! Finance]
1/23
12:05 am
vtrs
3 Reasons to Sell VTRS and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Sell VTRS and 1 Stock to Buy Instead [Yahoo! Finance]
1/20
07:15 am
vtrs
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure [Yahoo! Finance]
Low
Report
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure [Yahoo! Finance]
1/20
06:59 am
vtrs
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Low
Report
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
1/14
11:08 am
vtrs
"It Started With an Eye Exam" Campaign from Prevent Blindness Rolls Out in its Second Year to Share Stories on the Positive Impact of Access to Eye Care [Yahoo! Finance]
Low
Report
"It Started With an Eye Exam" Campaign from Prevent Blindness Rolls Out in its Second Year to Share Stories on the Positive Impact of Access to Eye Care [Yahoo! Finance]
1/8
09:32 am
vtrs
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer [Yahoo! Finance]
Low
Report
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer [Yahoo! Finance]
1/8
09:05 am
vtrs
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Low
Report
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
1/7
04:37 pm
vtrs
Assessing Idorsia (SWX:IDIA) Valuation After Recent Share Price Swings And Pipeline Developments [Yahoo! Finance]
Low
Report
Assessing Idorsia (SWX:IDIA) Valuation After Recent Share Price Swings And Pipeline Developments [Yahoo! Finance]
1/5
10:39 am
vtrs
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones [Yahoo! Finance]
Low
Report
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones [Yahoo! Finance]